Fosun Pharma's subsidiary acquires rights to AC-201 in China for RMB 156 million

August 29, 2025, ShanghaiFosun PharmaShanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Fosun Pharmaceutical Development Co., Ltd., has entered into a License Agreement with AccuraBio (Suzhou) Co., Ltd., under which AccuraBio grants Fosun Pharma exclusive rights in mainland China, Hong Kong, and Macau to research, develop, manufacture, register, and commercialize AC-201 and any pharmaceutical products containing AC-201 as the active ingredient for the diagnosis, prevention, and treatment of human diseases. This collaboration does not require approval from Fosun Pharma's board of directors or shareholders' meeting and does not constitute a related-party transaction.

Status of Licensed Products

AC-201 is an orally administered small-molecule JAK inhibitor independently developed by Aikeno, primarily intended for the treatment of autoimmune diseases. As of August 29, its first indication (moderate-to-severe plaque psoriasis) has completed a Phase II clinical trial in China. Data show that AC-201 demonstrated favorable safety and tolerability, with no serious adverse events observed. The Phase II clinical trial results for moderate-to-severe plaque psoriasis were positive, with all three dose groups achieving both the primary and key secondary endpoints after 12 weeks of treatment. According to the latest IQVIA MIDAS™ data, global sales of JAK inhibitors reached approximately 16.8 billion USD in 2024.

Counterparty Information

Aicono was established in December 2017, registered in Suzhou, Jiangsu Province, with Xiaohu Zhang as the legal representative. It is a company focused on the research and development of innovative small-molecule drugs. As of the announcement date, three drug candidates in its pipeline have entered clinical studies. Aicono has a registered capital of 43 million USD, with Aicono Biopharm (Hong Kong) Limited holding 100% equity and Xiaohu Zhang as the actual controller. Audited figures show that as of December 31, 2024, Aicono's total assets amounted to RMB 55.65 million, shareholders' equity to RMB 33.27 million, revenue for 2024 was RMB 0 million, and net profit was -RMB 60.4 million.

Key Points of the License Agreement

Cooperation Impact and Risk Notice

Fosun Pharma stated that this collaboration aims to fully leverage the group's strengths in drug clinical development, registration, manufacturing, and commercialization, further enriching its product pipeline and enhancing market positioning in the autoimmune disease field, thereby strengthening its core competitiveness in this therapeutic area. However, the clinical development, registration, manufacturing, and commercialization of the licensed product in the licensed territory are still subject to approvals from relevant regulatory authorities (including but not limited to the National Medical Products Administration), and given the inherent uncertainties in drug development, it is uncertain whether the licensed product will successfully complete the required clinical trials or obtain marketing approval. In addition, the sales performance of the licensed product after launch may be influenced by factors such as medical demand, market competition, and distribution channels, and thus also remains uncertain. Investors should be aware of investment risks.

Click to view the original announcement>>

Declaration: The market involves risks; investors should proceed with caution. This article is automatically published by an AI large model based on a third-party database. Any information appearing in this article (including but not limited to individual stocks, comments, predictions, charts, indicators, theories, or any form of statements) is provided solely for reference and does not constitute personal investment advice. Due to limitations such as the quality of third-party databases, we cannot verify the authenticity or completeness of the data; therefore, the content of this article may be inaccurate, incomplete, or misleading. Please refer to official company announcements for accurate information. For any questions, please contact biz@staff.sina.com.cn.

Editor: Xiaolang Express